GlassScriptPhysician profile
Bronwen S Greene
NPI 1952345449
$453.33
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2021: $107.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $107.09 | 2021 | |
| Pfizer INC. | $68.41 | 2019 | |
| Ironshore Pharmaceuticals INC. | $62.75 | 2019 | |
| Tris Pharma INC | $57.75 | 2019 | |
| Genentech USA, INC. | $44.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.83 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.25 | 2019 | |
| Kaleo, INC. | $14.00 | 2019 | |
| Sobi, INC | $13.27 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $13.16 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.38 | 2019 | |
| Adlon Therapeutics L.P. | $10.98 | 2019 | |
| Shire North American Group INC | $10.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bronwen Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.